PharmDecks

Course Content
Cardiovascular & Endocrine Pathophysiology

Introduction to Heart Failure

  • Heart failure is a chronic condition where the heart cannot pump blood effectively enough to meet metabolic demands.

  • Symptoms include:

    • Breathlessness

    • Fatigue

    • Fluid retention

  • Correct classification of heart failure is essential for appropriate medicine selection and counselling.


Classification of Heart Failure (UPDATED NICE)

Heart failure is classified based on left ventricular ejection fraction (LVEF).


Heart Failure with Reduced Ejection Fraction (HFrEF)

Definition

  • LVEF ≤40%

  • Impaired ventricular contraction (systolic dysfunction)

Common Causes

  • Ischaemic heart disease

  • Previous myocardial infarction

  • Hypertension

  • Dilated cardiomyopathy

Pharmacological Management

  • Core disease-modifying therapy

    • ACE inhibitor or ARB (or ARNI where appropriate)

    • Beta-blocker

    • Mineralocorticoid receptor antagonist

    • SGLT2 inhibitor

  • Diuretics

    • For symptom relief of congestion (not prognostic)


Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) (NEW NICE EMPHASIS)

Definition

  • LVEF 41–49%

Management

  • Offer an SGLT2 inhibitor (dapagliflozin)

  • Continue or consider:

    • ACE inhibitors or ARBs

    • Beta-blockers

    • MRAs

  • Diuretics for fluid overload


Heart Failure with Preserved Ejection Fraction (HFpEF) (UPDATED)

Definition

  • LVEF ≥50%

  • Impaired ventricular relaxation and filling (diastolic dysfunction)

Common Causes

  • Hypertension

  • Diabetes

  • Obesity

  • Atrial fibrillation

Pharmacological Management (UPDATED)

  • Offer an SGLT2 inhibitor (dapagliflozin)

  • Diuretics for congestion

  • Optimise treatment of comorbidities:

    • Blood pressure control

    • Rate/rhythm control in AF

    • Diabetes management


Comparison of Heart Failure Types

Feature HFrEF HFmrEF HFpEF
LVEF ≤40% 41–49% ≥50%
Main problem Poor contraction Mixed systolic/diastolic Poor relaxation
Disease-modifying therapy Strong evidence Emerging evidence Limited but improving
SGLT2 inhibitors Recommended Recommended Recommended

Conclusion

  • HF classification directly determines treatment strategy

  • SGLT2 inhibitors are now recommended across HFrEF, HFmrEF, and HFpEF

  • Pharmacists are essential in:

    • Medicine optimisation

    • Monitoring renal function and electrolytes

    • Supporting long-term adherence


References

  • NICE, “Chronic heart failure in adults: diagnosis and management”

  • British National Formulary, “Heart failure”

  • NHS, “Heart failure”

  • British Heart Foundation, “Types of heart failure”

0% Complete